Last updated: February 24, 2026
What is NDC 69315-0138?
NDC 69315-0138 is a pharmaceutical product approved by the U.S. Food and Drug Administration (FDA). It is a biosimilar or branded biologic, depending on the developer’s designation. The product’s specific details, including formulation and indications, are documented in the FDA database. This NDC is associated with a biologic used in treating conditions such as rheumatoid arthritis or certain cancers, depending on the molecule’s classification.
Market Landscape Overview
The biologic drug market is characterized by high prices driven by complex manufacturing and regulatory approval processes. Biosimilars, such as NDC 69315-0138, face a competitive environment with patent challenges and acceptance barriers. Historically, biosimilar entry reduces prices by 20–30%, but market uptake varies significantly.
Competitive Environment
- Major competitors: Original biologics (e.g., Enbrel, Humira) with patents expiring in recent years.
- Biosimilar entrants: Several competitors typically enter within 3–5 years post-patent expiry.
- Market share: Biosimilars have captured 10–30% of the biologic market segment within three years of launch.
- Pricing dynamics: Entry of biosimilars typically leads to price reductions of 15–35% relative to reference biologics.
Proven Launch Trends
| Year of Biosimilar Launch |
Price Reduction (vs. Reference) |
Market Share after 1 Year |
Regulatory Approach |
| 2018 |
20–25% |
10–15% |
European Union, U.S. pathways |
| 2020 |
15–30% |
20–25% |
U.S. approved biosaren-hp U.S. |
| 2022 |
25–30% |
25–35% |
Expanded indications, patent challenges |
Key Regulatory Milestones
- FDA approval process: Conditional on demonstrating biosimilarity or manufacturing equivalence.
- Interchangeability: Limited approval, essential for automatic substitution.
- Pricing regulation: No direct regulation; price is driven by market competition, payer negotiations, and managed care.
Price Projections
Launch Price Range
Historical biosimilar launches show initial pricing in the range of 15–25% discount to the reference biologic’s list price.
| Product Year |
Estimated Initial Commercial Price |
Discount vs. Reference |
Expected Launch Date |
| 2023–2024 |
$8,000–$12,000 per year |
20–25% off reference |
Pending FDA approval |
3-Year Outlook
Assuming market entry in 2024, prices are projected to decline an additional 10–20% over three years due to increased competition and payer negotiations. Capturing 20–35% of the market share may optimize revenue in this period.
Revenue Potential
| Scenario |
Market Share |
Price per Patient |
Yearly Revenue (per 1,000 patients) |
| Conservative |
15% |
$10,000 |
$15 million |
| Moderate |
25% |
$10,000 |
$25 million |
| Aggressive |
35% |
$10,000 |
$35 million |
Risks and Challenges
- Patent litigation delays.
- Slow adoption by prescribers constrained by existing biologic contracts.
- Payer resistance to price reductions.
- Regulatory delays or denials for interchangeability status.
Key Takeaways
- The NDC 69315-0138 biosimilar will compete mainly with high-value biologics, leading to initial prices 15–25% below reference drugs.
- Market penetration will likely reach 20–35% within three years of launch.
- Prices are expected to decline 10–20% over three years due to increased biosimilar competition.
- Revenue potential depends on market share captured, payer negotiations, and indication scope.
FAQs
What determines the initial price of a biosimilar?
Initial biosimilar pricing is mainly driven by manufacturing costs, development expenses, and market competition, typically setting at a 15–25% discount to reference biologics.
When will biosimilar NDC 69315-0138 likely launch?
Pending FDA approval, likely within the next 1–2 years based on current review timelines.
How will pricing evolve post-launch?
Prices tend to decrease by 10–20% over three years, influenced by market entry of additional biosimilars and payor negotiations.
What factors influence market share?
Regulatory approvals, physician acceptance, payer preferences, and patent litigation outcomes.
Are biosimilars subject to price regulation?
In the U.S., biosimilar prices are not directly regulated but are influenced by market competition and payer interventions.
References
- U.S. Food and Drug Administration. (2022). Biosimilar Development and Approval. https://www.fda.gov/drugs/biosimilars
- IQVIA. (2022). Biosimilar Market Analysis. IQVIA Reports.
- AZURO, D. et al. (2022). Impact of Biosimilar Entry on Prices and Market Share. Journal of Pharmaceutical Economics, 34(2), 144–157.
